Beijing InnoCare Pharma (HKG: 9969) has announced the first patient dosing in a clinical study of its protein tyrosine phosphatase (SHP2) allosteric inhibitor ICP-189 in China. The drug is being developed to treat liver cancer, head and neck cancer, digestive tract tumors, and other solid tumors.
Mechanism and Preclinical Results
ICP-189 is a highly selective oral inhibitor of SHP2, a non-receptor protein tyrosine phosphatase involved in the MAPK signaling and immune checkpoint pathways. It regulates cell proliferation and survival. Preclinical studies demonstrated good selectivity for other phosphatases and significant antitumor effects in various xenograft models.
Clinical Trial Progress
The drug received approval for an open, single-arm, multi-center Phase Ia/Ib clinical study in China in October 2021. A month later, the US FDA approved an open, single-arm, multi-center study assessing the drug’s safety, tolerability, pharmacokinetic characteristics, and efficacy in advanced solid tumors.-Fineline Info & Tech
